Cardiac Arrhythmias in Oncological Patients—Epidemiology, Risk Factors, and Management within the Context of the New ESC 2022 Guidelines

PURPOSE OF REVIEW: To provide an update on epidemiology, risk factors, and management of cardiac arrhythmias in oncological patients within the context of the new European Society of Cardiology 2022 guidelines on cardio-oncology. RECENT FINDINGS: One of the side effects of different chemotherapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Gawlik, Michał, Zimodro, Jakub Michal, Gąsecka, Aleksandra, Filipiak, Krzysztof J., Szmit, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556148/
https://www.ncbi.nlm.nih.gov/pubmed/37589940
http://dx.doi.org/10.1007/s11912-023-01445-x
_version_ 1785116816763256832
author Gawlik, Michał
Zimodro, Jakub Michal
Gąsecka, Aleksandra
Filipiak, Krzysztof J.
Szmit, Sebastian
author_facet Gawlik, Michał
Zimodro, Jakub Michal
Gąsecka, Aleksandra
Filipiak, Krzysztof J.
Szmit, Sebastian
author_sort Gawlik, Michał
collection PubMed
description PURPOSE OF REVIEW: To provide an update on epidemiology, risk factors, and management of cardiac arrhythmias in oncological patients within the context of the new European Society of Cardiology 2022 guidelines on cardio-oncology. RECENT FINDINGS: One of the side effects of different chemotherapeutics is their pro-arrhythmic activity. Both atrial and ventricular arrhythmias may be induced by cancer itself or by anticancer treatment. Recent studies report on the cardiotoxic activity of such promising therapies as BRAF and MEK inhibitors, or CAR-T therapy. SUMMARY: Risk factors of arrhythmias in oncological patients overlap with cardiovascular diseases risk factors, but there are some groups of anticancer drugs that increase the risk of cardiotoxicity. It is crucial to be aware of the risks associated with the oncological treatment and know how to act in case of cardiotoxicity.
format Online
Article
Text
id pubmed-10556148
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-105561482023-10-07 Cardiac Arrhythmias in Oncological Patients—Epidemiology, Risk Factors, and Management within the Context of the New ESC 2022 Guidelines Gawlik, Michał Zimodro, Jakub Michal Gąsecka, Aleksandra Filipiak, Krzysztof J. Szmit, Sebastian Curr Oncol Rep Article PURPOSE OF REVIEW: To provide an update on epidemiology, risk factors, and management of cardiac arrhythmias in oncological patients within the context of the new European Society of Cardiology 2022 guidelines on cardio-oncology. RECENT FINDINGS: One of the side effects of different chemotherapeutics is their pro-arrhythmic activity. Both atrial and ventricular arrhythmias may be induced by cancer itself or by anticancer treatment. Recent studies report on the cardiotoxic activity of such promising therapies as BRAF and MEK inhibitors, or CAR-T therapy. SUMMARY: Risk factors of arrhythmias in oncological patients overlap with cardiovascular diseases risk factors, but there are some groups of anticancer drugs that increase the risk of cardiotoxicity. It is crucial to be aware of the risks associated with the oncological treatment and know how to act in case of cardiotoxicity. Springer US 2023-08-17 2023 /pmc/articles/PMC10556148/ /pubmed/37589940 http://dx.doi.org/10.1007/s11912-023-01445-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Gawlik, Michał
Zimodro, Jakub Michal
Gąsecka, Aleksandra
Filipiak, Krzysztof J.
Szmit, Sebastian
Cardiac Arrhythmias in Oncological Patients—Epidemiology, Risk Factors, and Management within the Context of the New ESC 2022 Guidelines
title Cardiac Arrhythmias in Oncological Patients—Epidemiology, Risk Factors, and Management within the Context of the New ESC 2022 Guidelines
title_full Cardiac Arrhythmias in Oncological Patients—Epidemiology, Risk Factors, and Management within the Context of the New ESC 2022 Guidelines
title_fullStr Cardiac Arrhythmias in Oncological Patients—Epidemiology, Risk Factors, and Management within the Context of the New ESC 2022 Guidelines
title_full_unstemmed Cardiac Arrhythmias in Oncological Patients—Epidemiology, Risk Factors, and Management within the Context of the New ESC 2022 Guidelines
title_short Cardiac Arrhythmias in Oncological Patients—Epidemiology, Risk Factors, and Management within the Context of the New ESC 2022 Guidelines
title_sort cardiac arrhythmias in oncological patients—epidemiology, risk factors, and management within the context of the new esc 2022 guidelines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556148/
https://www.ncbi.nlm.nih.gov/pubmed/37589940
http://dx.doi.org/10.1007/s11912-023-01445-x
work_keys_str_mv AT gawlikmichał cardiacarrhythmiasinoncologicalpatientsepidemiologyriskfactorsandmanagementwithinthecontextofthenewesc2022guidelines
AT zimodrojakubmichal cardiacarrhythmiasinoncologicalpatientsepidemiologyriskfactorsandmanagementwithinthecontextofthenewesc2022guidelines
AT gaseckaaleksandra cardiacarrhythmiasinoncologicalpatientsepidemiologyriskfactorsandmanagementwithinthecontextofthenewesc2022guidelines
AT filipiakkrzysztofj cardiacarrhythmiasinoncologicalpatientsepidemiologyriskfactorsandmanagementwithinthecontextofthenewesc2022guidelines
AT szmitsebastian cardiacarrhythmiasinoncologicalpatientsepidemiologyriskfactorsandmanagementwithinthecontextofthenewesc2022guidelines

Ejemplares similares